文献速递基础与转化研究新药、器械与细胞基因治疗研发

在小鼠中通过碱基编辑纠正致病性线粒体DNA突变

Correcting a pathogenic mitochondrial DNA mutation by base editing in mice.
PubMed 文献 · Sci Transl Med · 2025-01-29

研究使用线粒体DddA衍生胞嘧啶碱基编辑器(DdCBE)在小鼠模型中引入补偿性编辑,以纠正线粒体tRNA丙氨酸(mt-tRNAAla)基因的致病突变。在突变细胞系中编辑后mt-tRNAAla量增加,最高达78%的mtDNA被编辑;通过AAV9静脉注射小鼠后,心脏和骨骼肌中mt-tRNAAla量呈剂量依赖性恢复,心脏乳酸水平降低。但最高剂量AAV9-DdCBE因产生广泛的mtDNA脱靶编辑而诱导严重不良效应。

要点

  • DdCBE可在突变细胞系中实现高达78% mtDNA的编辑并增加mt-tRNAAla量。
  • AAV9-DdCBE静脉注射小鼠后,心脏和骨骼肌中mt-tRNAAla量呈剂量依赖性恢复。
  • 最高剂量AAV9-DdCBE因广泛mtDNA脱靶编辑而诱导严重不良效应。

核心结论

  • DdCBE是线粒体疾病有前景的基因治疗工具,但治疗构建体的剂量必须仔细监测以避免有害的脱靶编辑。

研究设计与样本

  • 研究在小鼠模型中进行,该模型携带线粒体tRNA丙氨酸(mt-tRNAAla)基因的致病突变。
  • DdCBE基因构建体首先在m.5024C→T突变细胞系中测试,然后包装在重组腺相关病毒9(AAV9)中,通过眶后注射静脉给予小鼠。

主要发现

  • 在m.5024C→T突变细胞系中,编辑后mt-tRNAAla量增加,编辑高达78%的mtDNA。
  • 在经AAV9-DdCBE处理的小鼠中,心脏和骨骼肌观察到转导的DdCBE表达。
  • 通过m.5081G→A编辑,心脏和肌肉中总mt-tRNAAla量呈剂量依赖性恢复。
  • 心脏中增加的乳酸量在治疗小鼠中也降低。
  • 最高测试剂量的AAV9-DdCBE因产生广泛的mtDNA脱靶编辑而诱导严重不良效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 最高测试剂量的AAV9-DdCBE因产生广泛的mtDNA脱靶编辑而诱导严重不良效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary mitochondrial disorders are most often caused by deleterious mutations in the mitochondrial DNA (mtDNA). Here, we used a mitochondrial DddA-derived cytosine base editor (DdCBE) to introduce a compensatory edit in a mouse model that carries the pathological mutation in the mitochondrial transfer RNA (tRNA) alanine (mt-tRNAAla) gene. Because the original m.5024C→T mutation (G→A in the mt-tRNAAla) destabilizes the mt-tRNAAla aminoacyl stem, we designed a compensatory m.5081G→A edit (C→T in the mt-tRNAAla) that could restore the secondary structure of the tRNAAla aminoacyl stem. For this, the DdCBE gene construct was initially tested in an m.5024C→T mutant cell line. The reduced mt-tRNAAla amounts in these cells were increased after editing up to 78% of the mtDNA. Then, DdCBE was packaged in recombinant adeno-associated virus 9 (AAV9) and intravenously administered by retro-orbital injections into mice. Expression of the transduced DdCBE was observed in the heart and skeletal muscle. Total mt-tRNAAla amounts were restored in heart and muscle by the m.5081G→A edit in a dose-dependent manner. Lactate amounts, which were increased in the heart, were also decreased in treated mice. However, the highest dose tested of AAV9-DdCBE also induced severe adverse effects in vivo because of the extensive mtDNA off-target editing that it generated. These results show that although DdCBE is a promising gene therapy tool for mitochondrial disorders, the doses of the therapeutic constructs must be carefully monitored to avoid deleterious off-target editing.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Barrera-Paez JD, Bacman SR, Balla T, et al. Correcting a pathogenic mitochondrial DNA mutation by base editing in mice. Sci Transl Med. 2025. PMID: 39879319. doi:10.1126/scitranslmed.adr0792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。